Vericel Corporation Reports Strong 2024 Financial Growth

Vericel Corporation ( (VCEL) ) has released its Q4 earnings. Here is a breakdown of the information Vericel Corporation presented to its investors.

Vericel Corporation is a prominent player in the advanced therapies sector, focusing on sports medicine and severe burn care, with a distinctive portfolio of cell therapies and specialty biologics designed to repair injuries and restore lives. The company recently announced its financial results for the fourth quarter and full year of 2024, highlighting a significant 20% growth in total revenue to $237.2 million, driven by strong performances in both its MACI and Burn Care segments.

In the fourth quarter of 2024, Vericel reported a total net revenue of $75.4 million, marking a 16% increase from the previous year. The company’s MACI product, which saw a 21% revenue growth compared to the prior year, was a major contributor to this success. Additionally, the Burn Care segment, which includes Epicel and NexoBrid, also showed impressive growth. Vericel achieved a record gross margin of 78% for the quarter, alongside a notable net income increase of 52% to $19.8 million.

For the full year, Vericel’s adjusted EBITDA grew by 58% to $53.4 million, with a gross margin improvement to 73%. The company also reported a positive net income of $10.4 million, a significant turnaround from the previous year’s loss. These results were supported by strategic initiatives, including the successful launch of MACI Arthro and increased NexoBrid hospital orders.

Looking ahead, Vericel remains optimistic about its growth trajectory, reaffirming its 2025 financial guidance with an expected total revenue growth of 20% to 23%. The company is also focused on expanding its manufacturing capabilities and exploring opportunities to commercialize MACI outside the U.S., positioning itself for continued success in the coming years.